Securities Code: 300760 Securities Abbreviation: Mindray Medical Announcement No.: 2026-004
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Announcement on the Proposed Profit Distribution Plan for 2025
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
I. Deliberation Procedures
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (hereinafter referred to as the "Company") held the Sixteenth Meeting of the Eighth Board of Directors on March 27, 2026, which deliberated and approved the "Proposal on the Proposed Profit Distribution Plan for 2025". This proposal is still subject to the approval of the Company's shareholders' meeting.
II. Basic Situation of the Profit Distribution Plan
According to the audit report (EY Hua Ming (2026) Audit No. 70024693 H01) issued by EY Hua Ming Certified Public Accountants (Special General Partnership), the net profit attributable to the parent company owner in the consolidated financial statements for 2025 was RMB 8,135,775,409.00. In accordance with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law") and the "Articles of Association of Shenzhen Mindray Bio-Medical Electronics Co., Ltd." (hereinafter referred to as the "Articles of Association"), no further statutory surplus reserve shall be withdrawn once the cumulative amount of statutory surplus reserve reaches more than 50% of the share capital. As of December 31, 2018, the Company's statutory surplus reserve was RMB 607,845,633.00, which reached 50% of the total share capital. Therefore, no statutory surplus reserve was withdrawn thereafter until 2025. As of December 31, 2025, the Company's distributable profit was RMB 30,142,574,163.00.
- 2025 Profit Distribution Plan